SinoMab BioScience Voluntarily Withdraws BLA for Suciraslimab in China Citing Need for Additional Data
SinoMab BioScience Ltd (HKG: 3681) announced the voluntary withdrawal of its Biologics License Application (BLA)...
Mabwell Signs Licensing Agreement with Unilab for Denosumab Biosimilars in the Philippines
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced a licensing agreement with Unilab, Inc.,...
Innovent Biologics and JD Health Form Strategic Partnership to Enhance Drug Supply and Healthcare Services
China-based Innovent Biologics Inc., (HKG: 1801) and JD Health International Inc., (HKG: 6618) have officially...
Shanghai Henlius Biotech Initiates US Patient Dosing in Phase III Trial for HER2-Positive Gastric Cancer
China-based Shanghai Henlius Biotech Inc., (HKG: 2696) announced the first patient dosing in the US...
Bayer AG’s Kerendia Approved by FDA to Treat Adult Heart Failure with Ejection Fraction ≥40%
German pharmaceutical giant Bayer AG (ETR: BAYN) announced that it has received marketing approval from...
Sichuan Biokin’s Iza-bren Approved for Phase II Clinical Study in Renal Cell Carcinoma
China’s Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has received approval from the National Medical...
Hunan Mabgeek Biotech Files for Hong Kong IPO to Expand Innovative Biologics Pipeline
China-based Hunan Mabgeek Biotech Co., Ltd has submitted an application to the Hong Kong Stock...
GSK’s Arexvy RSV Vaccine Expansion for Adults 18-49 Receives FDA Review
UK-based GlaxoSmithKline (GSK; NYSE: GSK) announced that the U.S. Food and Drug Administration (FDA) has...
Dizal’s Sunvozertinib Included in NCCN Guidelines for EGFR Exon20ins NSCLC Treatment
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced the inclusion of its sunvozertinib (trade name:...
Boao Super Hospital Introduces Xiaflex for Non-Surgical Peyronie’s Disease Treatment
Boao Super Hospital in Hainan last week successfully introduced Xiaflex (collagenase clostridium histolyticum), a nonsurgical...
Lexenpharm Partners with AptarGroup for Single-Dose Nasal Spray Services in Greater China
China-based Lexenpharm late last week announced a strategic partnership with Aptar Pharma, a US-based global...
Eolas Therapeutics Gains Full Rights to AZD4041 for Opioid Use Disorder Development
US-based Eolas Therapeutics has entered into an agreement with its UK partner AstraZeneca (AZ, NASDAQ:...
Royal Philips and Suzhou Peixin Collaborate on AI-Powered Interventional Therapy Platform for Structural Heart Disease
Dutch device giant Royal Philips (NYSE: PHG) and China-based Suzhou Peixin Technology Co., Ltd. late...
YolTech Therapeutics Receives NMPA Clearance for YOLT-101 in HeFH Clinical Study
Shanghai-based YolTech Therapeutics announced that it has received clearance from the National Medical Products Administration...
CARsgen Therapeutics Secures European Patent for GPC3 CAR-T Technology After Successful Opposition Proceedings
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced a favorable outcome in the opposition proceedings...
Eisai Announces Commercial Release of Urece (Dotinurad) from Suzhou Facility in China
Japan-based Eisai (TYO: 4523) announced the official commercial release of the first batch of its...
InnoCare Pharma Receives FDA Approval for Mesutoclax in Myeloid Malignancies
Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has received clinical trial...
Pfizer and Astellas’ Xtandi Shows Positive Results in Phase III EMBARK Study for Prostate Cancer
Partners Pfizer (NYSE: PFE) and Astellas Pharma Inc. (TYO: 4503) announced positive topline results from...
Bayer’s Elinzanetant Granted UK Marketing Authorization for Menopause-Related Vasomotor Symptoms
Germany’s Bayer (ETR: BAYN) this week announced that the UK Medicines and Healthcare products Regulatory...
AbbVie Licenses IGI Therapeutics’ ISB 2001 for Oncology and Autoimmune Diseases
US-based AbbVie (NYSE: ABBV) this week announced a licensing agreement with IGI Therapeutics SA, a...